Indonesia: vaccines market revenue 2029

The revenue in the 'Vaccines' segment of the pharmaceuticals market in Indonesia was forecast to decrease between 2024 and 2029 by in total 191.3 million U.S. dollars (-30.65 percent). This overall decrease does not happen continuously, notably not in 2028 and 2029. The indicator is estimated to amount to 432.97 million U.S. dollars in 2029.

The Statista Market Insights cover a broad range of additional markets.

Revenue of the vaccines market in Indonesia from 2020 to 2029 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Citation formats